Delayed Release Valproic Acid Formulations for PAI-1 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for preventing and treating thrombotic events, such as myocardial infarction and stroke, are insufficient in reducing the incidence of hazardous tissue ischemia, particularly in patients with cardiovascular risk factors, as they fail to effectively enhance endogenous fibrinolysis and inhibit plasminogen activator inhibitor-1 (PAI-1) levels, which are elevated in conditions like obesity and metabolic syndrome.
Innovation Solution
Pharmaceutical formulations of valproic acid (VPA) or its pharmaceutically acceptable salts, designed for delayed release, are administered to coincide with peak PAI-1 plasma levels, thereby inhibiting PAI-1 activity and enhancing tissue-type plasminogen activator (t-PA) effects, thereby preventing pathological conditions associated with excess fibrin deposition and thrombus formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antiplatelet drugs and oral anticoagulants are used to prevent clot formation, then thrombus prevention is improved, but fibrinolytic capacity remains insufficient and PAI-1 levels are not effectively inhibited
Solution Approach 1:
The patent introduces HDAC inhibitors (such as valproic acid) as intermediary substances that mediate between platelet inhibition and fibrinolytic enhancement. These inhibitors act as molecular mediators that suppress PAI-1 expression while maintaining platelet anti-aggregation effects, thereby resolving the contradiction between thrombus prevention and fibrinolytic insufficiency
Solution Approach 2:
The patent combines multiple mechanisms of action into a composite therapeutic approach: HDAC inhibition for epigenetic regulation, platelet anti-aggregation, and fibrinolytic enhancement. This composite strategy simultaneously addresses thrombus prevention and fibrin deposition by integrating multiple biological pathways rather than relying on single-mechanism drugs
2Object-generated harmful factors
If HDAC inhibitors are administered to inhibit PAI-1 levels, then fibrinolytic capacity is enhanced, but plasma concentration timing must be precisely controlled to coincide with peak PAI-1 levels
Solution Approach 1:
The patent applies preliminary action by administering HDAC inhibitors in advance of peak PAI-1 levels. The delayed-release formulation is designed to release the inhibitor progressively, ensuring that therapeutic plasma concentrations are achieved before the peak PAI-1 occurs, thereby proactively suppressing PAI-1 rather than reacting after it peaks
Solution Approach 2:
The patent employs dynamics by using a delayed-release formulation that dynamically adjusts the release rate of the HDAC inhibitor. The formulation's release characteristics are tailored to match the circadian rhythm of PAI-1, creating a dynamic plasma concentration profile that coincides with peak PAI-1 levels rather than maintaining static concentrations
3Reliability
If delayed-release formulations are used to coincide with peak PAI-1 levels, then therapeutic efficacy is improved, but formulation design and plasma concentration monitoring become more complex
Solution Approach 1:
The patent applies parameter changes by modifying the release rate parameter of the formulation to match the temporal profile of PAI-1. The delayed-release characteristics are specifically tuned to release the HDAC inhibitor at a rate that coincides with peak PAI-1 levels, transforming the plasma concentration-time profile to achieve optimal therapeutic efficacy
Data Source
AI summary
There is provided herein a pharmaceutical formulation having one or more component comprising valproic acid (VPA) and/or a pharmaceutically acceptable salt thereof; and one or more secondary acid, and optionally comprising one or more pharmaceutically acceptable excipient. There is also provided uses of such formulations.